AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose-ranging study
- 1 April 2009
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7 (4), 566-572
- https://doi.org/10.1111/j.1538-7836.2009.03301.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prevention of Venous ThromboembolismChest, 2008
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- Prevention of Venous Thromboembolic Disease Following Primary Total Knee ArthroplastyThe Journal of Bone and Joint Surgery-American Volume, 2001
- A meta-analysis of thromboembolic prophylaxis in total knee arthroplastyThe Journal of Arthroplasty, 2001
- Prevention of Venous Thromboembolism after Knee ArthroplastyAnnals of Internal Medicine, 1996
- Sample size for a dose-response studyJournal of Biopharmaceutical Statistics, 1992
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972